SCHEMBL3159277

SCHEMBL3159277

CCOC(=O)c1cccc(C#CCN2CCN(c3nccs3)CC2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
LMNA P02545 2/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
PRMT1 Q99873 1/20 0.39
ACACB O00763 1/20 0.39
JMJD6 Q6NYC1 2/20 0.39
PIK3CA P42336 1/20 0.39
SLC6A7 Q99884 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 1/20 0.39
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 1/20 0.38
PTK2 Q05397 1/20 0.38
RXFP1 Q9HBX9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3155636 0.91 DRD2 (0.43) DRD2DRD4LMNAMAPK1RAB9A
SCHEMBL3151993 0.88 RAB9A (0.43) DRD2DRD4LMNAMAPK1RAB9A
SCHEMBL3148169 0.86 LMNA (0.46) DRD2DRD4LMNAMAPK1RAB9A
SCHEMBL3151959 0.85 LMNA (0.43) DRD2DRD4LMNAMAPK1RAB9A
SCHEMBL3159282 0.85 SLC6A7 (0.43) DRD2DRD4MAPK1ACACBJMJD6
SCHEMBL3156513 0.85 DRD2 (0.44) DRD2DRD4LMNAMAPK1RAB9A
SCHEMBL3151241 0.85 RAB9A (0.41) DRD2DRD4LMNAMAPK1RAB9A
SCHEMBL3151761 0.82 DRD2 (0.40) DRD2DRD4RAB9ASLC6A7MEN1
SCHEMBL3154951 0.82 ALOX5 (0.41) DRD2DRD4RAB9ASLC6A7MEN1
Hydrochloric Acid SCHEMBL3164152 0.81 ALOX5 (0.41) DRD2DRD4RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765816-B1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS GRUENENTHAL GMBH (DE) 2010-03-10 EP claimed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 US claimed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 US disclosed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRM5, GRIK5, GRM1 DRD2 457/4885DRD4 871/4885LMNA 2615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.